Download PDF
Thromb Haemost 2007; 98(05): 1141-1142
DOI: 10.1160/TH07-04-0263
Case Report
Schattauer GmbH

Perioperative myocardial infarction in a patient receiving low-dose prothrombin complex concentrates

Catherine N. Bagot
1   Department of Haematology, King’s College Hospital, Denmark Hill, London, UK
,
Roman Cregg
2   Department of Anaesthetics, King’s College Hospital, Denmark Hill, London, UK
,
Raj K. Patel
1   Department of Haematology, King’s College Hospital, Denmark Hill, London, UK
,
Amina Shariff
2   Department of Anaesthetics, King’s College Hospital, Denmark Hill, London, UK
,
Roopen Arya
1   Department of Haematology, King’s College Hospital, Denmark Hill, London, UK
› Author Affiliations
Further Information

Publication History

Received 11 April 2007

Accepted after resubmission 31 July 2007

Publication Date:
30 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): 3rd edition – 2005 update. Br J Haematol 2005; 132: 277-285.
    PubMedGoogle Scholar
  • 2 Boulis NB, Bobek MP, Schmaier A. et al. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45: 1113-1119.
    CrossrefPubMedGoogle Scholar
  • 3 Cartmill M, Dolan G, Byrne JL. et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergency. Br J Neurosurg 2000; 14: 458-461.
    CrossrefPubMedGoogle Scholar
  • 4 Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anti-coagulation after intracerebral hemorrhage. Stroke 1992; 23: 972-977.
    CrossrefPubMedGoogle Scholar
  • 5 Van Aart L, Eijkhout HW, Kamphuis JS. et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial. Thromb Res 2006; 118: 313-320.
    CrossrefPubMedGoogle Scholar
  • 6 Yasaka M, Sakata T, Naritomi H. et al. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005; 115: 455-459.
    CrossrefPubMedGoogle Scholar
  • 7 Kasper CK. Thromboembolic complications – Task Force Report. Thromb Diath Haemorrh 1975; 33: 640-644.
    PubMedGoogle Scholar
  • 8 Aledort LM. Factor IX and thrombosis. Scand J Haematol 1977; 30 (Suppl): 40-42.
    PubMedGoogle Scholar
  • 9 Magner A, Aronson D. Toxicity of factor IX concentrates in mice. Dev Biol Stand 1979; 44: 185-188.
    PubMedGoogle Scholar
  • 10 Kohler M, Heiden M, Harbauer G. et al. Comparison of different prothrombin complex concentrates: In vitro and in vivo studies. Thromb Res 1990; 60: 63-70.
    CrossrefPubMedGoogle Scholar
  • 11 Seligsohn U, Kasper CK, Osterud B. et al. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828-837.
    PubMedGoogle Scholar
  • 12 Gray E, Tubbs J, Thomas S. et al. Measurement of activated factor IX in factor IX concentrates: Correlation with in vivo thrombogenicity. Thromb Haemost 1995; 73: 675-679.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Hellstern P, Kohler M. Prothrombin complex concentrates (PCC) and thromboembolic complications. Ann Hematol 1995; 70 (Suppl I): A88.
    PubMedGoogle Scholar
  • 14 Lusher JM. Prediction and management of adverse events associated with the use of factor IX complex concentrates. Semin Hematol 1993; 30 (2 Suppl 1): 36-40.
    PubMedGoogle Scholar
  • 15 Reiss HB, Meier-Hellmann A, Motsch J. et al. Prothrombin complex concentrate (Octaplex®) in patients requiring immediate reversal of oral anticoagulation. Thromb Res. 2007 in press.
    PubMedGoogle Scholar
  • 16 Girolami G, Ruzzon E, Fabris F. et al. Myocardial infarction and other arterial occlusions in haemophilia A patients. Acta Haematol 2006; 116: 120-125.
    CrossrefPubMedGoogle Scholar